Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

GlaxoSmithKline Appeals Over Argentine Baby Drug Trial Fine

By International Business TimesMarket OverviewJan 07, 2012 03:27AM ET
www.investing.com/analysis/glaxosmithkline-appeals-over-argentine-baby-drug-trial-fine-110578
GlaxoSmithKline Appeals Over Argentine Baby Drug Trial Fine
By International Business Times   |  Jan 07, 2012 03:27AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
Pharmaceutical giants GlaxoSmithKline Argentina Laboratories is to appeal against a fine for "irregularities" during clinical drug trials involving babies.

The 400,000 pesos (£60,000) fine was issued by a Buenos Aires court after a report by the National Administration of Medicine, Food and Tech-nology (ANMAT), which accused the drug maker of experimenting with humans and falsifying parental authorisation documents so that babies could be part of the vaccine trials conducted by the laboratory between 2007 and 2008.

The trials gained attention in Argentina after the Buenos Aires Herald reported that during the studies 14 babies died. They had taken part in trials on the Synflorix vaccine, which the company says protects against bacterial pneumonia and meningitis.

GSK Argentina medical director Rosana Felice categorically denied that the vaccine was responsible for the deaths.

"Any deaths in the study have been thoroughly and independently investigated and it has been concluded that none of the deaths were related to the vaccine they were given," she said.

"In no case was it related to the administration of the vaccine and this has been sufficiently demonstrated, proven and evaluated by ANMAT."
Since 2007, 15,000 babies under the age of one were recruited for the GlaxoSmithKline trials. Many of the babies came from poor families in Mendoza, San Juan and Santiago del Estero.

Judge Marcelo Aguinsky fined the company after ruling that it was responsible for "irregularities" during the recruitment process of young children. He also fined two participating doctors £45,000 each for their roles in the trials.

The judge ruled that many of the consent forms were "signed" by illiterate parents or by people who did not have legal custody of the children.

"These doctors took advantage of many illiterate parents who take their children [to hospital] for treatment by pressuring and forcing them into signing these 28-page consent forms and getting them involved in the trials," said paediatrician Ana Marchese, who was working at the Eva Perón children's public hospital in Santiago del Estero when the studies were being conducted.

Marchese added: "In various cases, the doctors who had conducted the trials did not answer the calls made by the worried parents after witnessing their babies' reactions to the vaccines," she told the Buenos Aires Herald.

"It is important to note that the ANMAT's ruling does not in any way question the safety of the study vaccine, Synflorix," added GlaxoSmithKline Argentina Laboratories in a statement.

"The ANMAT ruling relates to the clinical trial process and not the vaccine," which was approved by the agency for sale in 2009.
GlaxoSmithKline Appeals Over Argentine Baby Drug Trial Fine
 

Related Articles

GlaxoSmithKline Appeals Over Argentine Baby Drug Trial Fine

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. This is not a solicitation or inducement to buy, sell, subscribe, or underwrite securities or units. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment. This document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. It may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance.
Continue with Google
or
Sign up with Email